Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

被引：0

作者：

Schjesvold, Fredrik H. ^{[1
,2
]}

Ludwig, Heinz ^{[3
]}

Delimpasi, Sossana ^{[4
,5
]}

Robak, Pawel ^{[6
]}

Coriu, Daniel ^{[7
]}

Tomczak, Waldemar ^{[8
,9
]}

Pour, Ludek

Spicka, Ivan

Dimopoulos, Meletios-Athanasios ^{[10
]}

Masszi, Tamas ^{[11
]}

Chernova, Natalia G. ^{[12
]}

Sandberg, Anna ^{[13
]}

Thuresson, Marcus ^{[13
]}

Norin, Stefan ^{[13
]}

Bakker, Nicolaas A. ^{[13
]}

Mateos, Maria-Victoria ^{[14
]}

Richardson, Paul G. ^{[15
]}

Sonneveld, Pieter ^{[16
]}

机构：

[1] Univ Oslo, Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[3] Wilhelminen Canc Res Inst, Ctr Med Oncol & Hematol, Dept Med 1, Outpatient Dept & Palliat Care, Vienna, Austria

[4] Evangelismos Med Ctr, Bone Marrow Transplantat Unit, Athens, Greece

[5] Evangelismos Med Ctr, Dept Hematol, Athens, Greece

[6] Univ Hosp Ostrava, Dept Hemato Oncol, Ostrava, Czech Republic

[7] Univ Med & Pharm Carol Davila, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[8] Med Univ Lublin, Dept HematoOncol, Lublin, Poland

[9] Med Univ Lublin, Bone Marrow Transplantat, Lublin, Poland

[10] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece

[11] Semmelwe Univ, Dept Internal Med & Hematol, Budapest, Hungary

[12] Natl Res Ctr Hematol, Moscow, Russia

[13] Oncopeptides AB, Stockholm, Sweden

[14] Hosp Clin Univ Salamanca, IBSAL, CIC, Salamanca, Spain

[15] Dana Farber Canc Inst, USA, Boston, MA USA

[16] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2331 / 2336

页数：6

共 50 条

[1] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Schjesvold, Fredrik H.
Ludwig, Heinz
Delimpasi, Sossana
Robak, Pawel
Coriu, Daniel
Tomczak, Waldemar
Pour, Ludek
Spicka, Ivan
Dimopoulos, Meletios-Athanasios
Masszi, Tamas
Chernova, Natalia G.
Sandberg, Anna
Thuresson, Marcus
Norin, Stefan
Bakker, Nicolaas A.
Mateos, Maria-Victoria
Richardson, Paul G.
Sonneveld, Pieter
[J]. REVISTA CHILENA DE LITERATURA, 2024, (109): : 2331 - 2336
[2] OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma
Schjesvold, Fredrik
Robak, Pawel
Pour, Ludek
Aschan, Johan
Sonneveld, Pieter
[J]. FUTURE ONCOLOGY, 2020, 16 (11) : 631 - 641
[3] Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
Larocca, Alessandra
Leleu, Xavier
Touzeau, Cyrille
Blade, Joan
Paner, Agne
Mateos, Maria-Victoria
Cavo, Michele
Maisel, Christopher
Alegre, Adrian
Oriol, Albert
Raptis, Anastasios
Rodriguez-Otero, Paula
Mazumder, Amitabha
Laubach, Jacob
Nadeem, Omar
Sandberg, Anna
Orre, Marie
Torrang, Anna
Bakker, Nicolaas A.
Richardson, Paul G.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (03) : 639 - 648
[4] Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma
Kyriakou, Charalampia
Murphy, Philip
Petrucci, Maria Teresa
Bacon, Pamela
Lewis, Philip
Gilet, Helene
Arnould, Benoit
Vande Broek, Isabelle
Leleu, Xavier
[J]. BLOOD, 2015, 126 (23)
[5] OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide
Sonneveld, Pieter
Schjesvold, Fredrik
Robak, Pawel
Rossjey, Viktor
Pour, Ludk
Minarik, Jiri
Delimpasi, Sosana
Legic, Wojciech
Salogub, Galina
Harmenberg, Johan
Byrne, Catriona
Nordstrom, Eva
Richardson, Paul G.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S25 - S25
[6] Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Hungria, Vania
Beksac, Meral
Weisel, Katja C.
Nooka, Ajay K.
Masszi, Tamas
Spicka, Ivan
Munder, Markus
Mateos, Maria-Victoria
Mark, Tomer M.
Qi, Ming
Qin, Xiang
Fastenau, John
Spencer, Andrew
Sonneveld, Pieter
Garvin, Wendy
Renaud, Thomas
Gries, Katharine S.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 561 - 569
[7] Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Ludwig, Heinz
Moreau, Philippe
Dimopoulos, Meletios A.
Mateos, Maria-Victoria
Kaiser, Martin
Hajek, Roman
Feng, Shibao
Cocks, Kim
Buchanan, Jaqueline
Weisel, Katja
[J]. BLOOD CANCER JOURNAL, 2019, 9 (3)
[8] Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Heinz Ludwig
Philippe Moreau
Meletios A. Dimopoulos
Maria-Victoria Mateos
Martin Kaiser
Roman Hajek
Shibao Feng
Kim Cocks
Jaqueline Buchanan
Katja Weisel
[J]. Blood Cancer Journal, 9
[9] Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
Houghton, Katherine
Dimopoulos, Meletios A.
Lin, Peggy
Guillonneau, Sophie
Bury, Denise
Attal, Michel
Richardson, Paul G.
Delforge, Michel
[J]. BLOOD, 2019, 134
[10] Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
Siegel, David
Weisel, Katja
Zahlten-Kumeli, Anita
Medhekar, Rohan
Ding, Bifeng
Leleu, Xavier
[J]. LEUKEMIA & LYMPHOMA, 2021, 62 (12) : 3002 - 3010

← 1 2 3 4 5 →